Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 18 Squamous Cell Carcinoma of Head and Neck 11 Head and Neck Neoplasms 9 Recurrence 2 Nasopharyngeal Neoplasms 2 Pathologic Complete Response 1 Oropharyngeal Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Diseases 1 Hypopharyngeal Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 24 pembrolizumab 23 Magnetic Resonance Spectroscopy 19 Specimen Handling 16 Radiotherapy, Intensity-Modulated 12 Carboplatin 12 Cetuximab 11 1,2-diaminocyclohexaneplatinum II citrate 10 Platinum 9 Paclitaxel 9 Radiotherapy 6 Radiation 6 Fluorouracil 6 Biopsy 5 Taxes 4 Nivolumab 4 Docetaxel 4 (225)Ac-DOTA-c(RGDyK) 4 X-Rays 3 Pemetrexed 3 Fluorodeoxyglucose F18 3 reolysin 2 pralsetinib 2 ipatasertib 2 cemiplimab 2 atezolizumab 2 Surgical Procedures, Operative 2 Standard of Care 2 Radiotherapy, Image-Guided 2 Radiosurgery 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × nimotuzumab × Head & Neck × Clear all

NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn

Carcinoma, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡